Relationships of Thyroid Hormone and proBDNF with Depression

doi:10.12114/j.issn.1007-9572.2020.00.068

Abstract

Abstract: Background　With the deepening understanding of depression，it has been found that depression is not only a neurodegenerative disease，but also closely related to the hypothalamus pituitary thyroid axis（HPT axis）.The neurotrophic hypothesis of depression suggests that the precursor of brain-derived neurotrophic factor（proBDNF）plays a role in the pathogenesis of depression，but the relationships of depression with thyroid hormone and proBDNF are rarely studied.Objective　To investigate the relationships of proBDNF and thyroid hormone level with depression.Methods　Forty-three inpatients and outpatients with depression（case group）and 31 healthy examinees（control group）from the Mental Hospital of Yunnan Province were enrolled during October 2017 to June 2018.General information and levels of thyroid hormone〔triiodothyronine（T3），thyroxine（T4），free triiodothyronine（FT3），free thyroxine（FT4），thyrotropin（TSH）and proBDNF〕were collected and compared between the two groups.The relationships of levels of thyroid hormone and proBDNF with the total and subscale scores of HAMD-24 were analyzed.The correlation between thyroid hormone and proBDNF level was assayed.Results　There were no significant differences in mean T3 and FT4 levels between the two groups（P>0.05）.Mean T4，FT3 and TSH levels in the case group were lower than those in the control group（P<0.05）.The level of FT3 was positively correlated with the total score of HAMD-24 and the score of cognitive impairment subscale in the case group（P<0.05）.There was no significant difference of proBDNF level between the two groups（P>0.05）.In the case group，the proBDNF level was not correlated with the total score and subscale scores of HAMD-24（P>0.05）.And there was no correlation between thyroid hormone level and proBDNF level（P>0.05）.Conclusion　Depression patients are more prone to anxiety，suicide，paranoia，obsession，despair and sleeping problems，and may have hypothyroidism.

Key words: Depressive disorder, Thyroid hormone, Precursor of brain-derived neurotrophic factor, Hypothalamus pituitary thyroid axis

摘要： 背景　随着对抑郁症了解的深入，人们发现其不仅是一种神经退行性疾病，同时还与下丘脑-垂体-甲状腺轴（HPT轴）密切相关，而抑郁症的神经营养因子假说则认为脑源性神经营养因子前体（proBDNF）在抑郁症的发病过程中发挥着一定作用，但抑郁症、HPT轴和proBDNF三者间的关系却鲜有研究。目的　探索甲状腺激素、proBDNF水平与抑郁症之间的关系。方法　选取2017年10月—2018年6月在云南省精神病医院住院及门诊治疗的抑郁症患者43例为病例组。同期选取本院健康体检者31例为对照组。测定并比较两组一般资料及甲状腺激素〔三碘甲状腺原氨酸（T3）、甲状腺素（T4）、游离三碘甲状腺原氨酸（FT3）、游离甲状腺素（FT4）、促甲状腺激素（TSH）〕、proBDNF水平；分析病例组甲状腺激素、proBDNF水平与汉密尔顿抑郁量表24项（HAMD-24）总分及其各因子评分之间的相关性，甲状腺激素与proBDNF水平的相关性。结果　两组T3、FT4水平比较，差异无统计学意义（P>0.05）；病例组T4、FT3、TSH水平低于对照组（P<0.05）。病例组FT3水平与HAMD-24总分及认知障碍评分呈正相关（P<0.05）。两组proBDNF水平比较，差异无统计学意义（P>0.05）。病例组proBDNF水平与HAMD-24总分及其各因子评分均无相关性（P>0.05）。病例组甲状腺激素水平与proBDNF水平无相关性（P>0.05）。结论　抑郁症患者更容易出现焦虑、自杀、偏执、强迫、绝望感及睡眠障碍等问题，且有并发甲状腺功能减退的可能。

关键词: 抑郁症, 甲状腺激素, 脑源性神经营养因子前体, 下丘脑-垂体-甲状腺轴

WANG Na,FU Xiyue,ZHANG Fan, et al. Relationships of Thyroid Hormone and proBDNF with Depression　[J]. Chinese General Practice, 2020, 23(9): 1100-1104. DOI: 10.12114/j.issn.1007-9572.2020.00.068.
王娜,傅希玥,张帆等. 甲状腺激素及脑源性神经营养因子前体水平与抑郁症的关系研究[J]. 中国全科医学, 2020, 23(9): 1100-1104. DOI: 10.12114/j.issn.1007-9572.2020.00.068.

References

［1］CHAKRABORTY G，MAGAGNA-POVEDA A，PARRATT C，et al．Reduced hippocampal brain-derived neurotrophic factor（BDNF）in neonatal rats after prenatal exposure to propylthiouracil（PTU）［J］．Endocrinology，2012，153（3）：1311-1316．DOI：10.1210/en.2011-1437.
［2］KOBAYASHI K，TSUJI R，YOSHIOKA T，et al．Perinatal exposure to PTU delays switching from NR2B to NR2A subunits of the NMDA receptor in the rat cerebellum［J］．Neurotoxicology，2006，27（2）：284-290．DOI：10.1016/j.neuro.2005.11.008.
［3］KAREGE F，PERRET G，BONDOLFI G，et al．Decreased serum brain-derived neurotrophic factor levels in major depressed patients［J］．Psychiatry Res，2002，109（2）：143-148．DOI：10.1016/s0165-1781（02）00005-7.
［4］ZHOU L，XIONG J，LIM Y，et al．Upregulation of blood proBDNF and its receptors in major depression［J］．J Affect Disord，2013，150（3）：776-784．DOI：10.1016/j.jad.2013.03.002.
［5］卢瑾，李凌江，许秀峰.中国抑郁障碍防治指南（第二版）解读：评估与诊断［J］．中华精神科杂志，2017，50（3）：169-171．DOI：10.3760/cma.j.issn.1006-7884.2017.03.003.
［6］汤毓华，张明园.汉密顿抑郁量表（HAMD）［J］．上海精神医学，1984（2）：6165.
［7］张利红，张玲，黎海涛，等．甲状腺功能亢进伴精神神经症状患者脑功能区研究［J］．第三军医大学学报，2013，35（23）：2573-2576．DOI：10.16016/j.1000-5404.2013.23.012.
ZHANG L H，ZHANG L，LI H T，et al．Functional areas of brain in hyperparathyroidism patients with neuropsychiatric symptoms［J］．Acta Academiae Medicinae Militaris Tertiae，2013，35（23）：2573-2576．DOI：10.16016/j.1000-5404.2013.23.012.
［8］ZHANG Z J，QIANG L I，KANG W H，et al．Differences in hypothyroidism between lithium-free and -treated patients with bipolar disorders［J］．Life Sci，2006，78（7）：771-776．DOI：10.1016/j.lfs.2005.05.090.
［9］BROUWER J P，APPELHOF B C，HOOGENDIJK W J，et al．Thyroid and adrenal axis in major depression：a controlled study in outpatients［J］．Eur J Endocrinol，2005，152（2）：185-191．DOI：10.1530/eje.1.01828.
［10］蔡文治，金燕君，陈文泽，等．中国人群单相抑郁症和双相抑郁障碍与促甲状腺激素关系的meta分析［J］．中国慢性病预防与控制，2016，24（5）：387-391．DOI：10.16386/j.cjpccd.issn.1004-6194.2016.05.022.
［11］王小泉，王祖森，侯正华，等．单、双相抑郁症临床特征及血清甲状腺激素水平比较［J］．精神医学杂志，2015，28（3）：182-185.
［12］LARSEN P R，SILVA J E，KAPLAN M M.Relationships between circulating and intracellular thyroid hormones：physiological and clinical implications［J］．Endocr Rev，1981，2（1）：87-102．DOI：10.1210/edrv-2-1-87.
［13］WHYBMW P C，PRANGE A J Jr.A hypothesis of thyroid-catecholamine-receptor interaction.Its relevance to affective illness［J］．Arch Gen Psychiatry，1981，38（1）：106-113．DOI：10.1001/archpsyc.1981.01780260108012.
［14］VAIDYA V A，MAREK G J，AGHAJANIAN G K，et al．5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex［J］．J Neurosci，1997，17（8）：2785-2795.
［15］ZETTERSTR?M T S，PEI Q，MADHAV T R，et al．Manipulations of brain 5-HT levels affect gene expression for BDNF in rat brain［J］．Neuropharmacology，1999，38（7）：1063-1073．DOI：10.1016/s0028-3908（99）00022-2.
［16］SHULGA A，BLAESSE A，KYSENIUS K，et al．Thyroxin regulates BDNF expression to promote survival of injured neurons［J］．Mol Cell Neurosci，2009，42（4）：408-418．DOI：10.1016/j.mcn.2009.09.002.
［17］DINIZ C R A F，CASAROTTO P C，RESSTEL L，et al．Beyond good and evil：a putative continuum-sorting hypothesis for the functional role of proBDNF/BDNF-propeptide/mBDNF in antidepressant treatment［J］．Neurosci Biobehav Rev，2018，90：70-83．DOI：10.1016/j.neubiorev.2018.04.001.
［18］JIANG H，CHEN S，LI C，et al．The serum protein levels of the tPA-BDNF pathway are implicated in depression and antidepressant treatment［J］．Transl Psychiatry，2017，7（4）：e1079．DOI：10.1038/tp.2017.43.
［19］SINHA R A，PATHAK A，KUMAR A，et al．Enhanced neuronal loss under perinatal hypothyroidism involves impaired neurotrophic signaling and increased proteolysis of p75（NTR）［J］．Mol Cell Neurosci，2009，40（3）：354-364．DOI：10.1016/j.mcn.2008.12.001.

[1]	ZHANG Jin, DING Zhiguo, QI Shuo, LI Ying, LI Weiqiang, ZHANG Yuanyuan, ZHOU Tong. Relationship between Serum Thyroid Hormone Levels and Prognosis during Hospitalization in Heart Failure Patients [J]. Chinese General Practice, 2023, 26(33): 4125-4129.
[2]	REN Yanfeng, LIU Shimeng, TAO Ying, CHEN Yingyao. A Systematic Review of Medication Preferences for Patients with Depression Based on Discrete Choice Experiment and Best-worst Scaling [J]. Chinese General Practice, 2023, 26(28): 3559-3564.
[3]	LIANG Xuemei, WANG Rui, ZHAO Yuhuan, XU Tianjiao, WANG Wei, SUN Weidong. Transcranial Low-level Laser Therapy: a Novel Treatment for Depression [J]. Chinese General Practice, 2023, 26(27): 3335-3341.
[4]	FENG Xiaoling, YIN Wenqing, WANG Ying, HOU Lihui. Correlation Analysis between Different Free Testosterone Index Levels and Clinical Characteristics of Patients with Polycystic Ovary Syndrome [J]. Chinese General Practice, 2023, 26(24): 3005-3009.
[5]	ZHA Qianqian, XU Lianying, CHEN Juan, HUANG Wen, ZHANG Xinqiong. Summary of Best Evidence for Prevention of Recurrence of Late-life Depression [J]. Chinese General Practice, 2023, 26(19): 2332-2338.
[6]	DU Yeming, ZHANG Yunqiao, WANG Zongqi, MIN Xue, CUI Yalian, WANG Yanfang. Characteristics of Somatic Symptoms and Their Correlations with Brain-derived Neurotrophic Factor and Inflammatory Cytokinesin Patients with Major Depressive Disorder [J]. Chinese General Practice, 2023, 26(12): 1463-1471.
[7]	YAN Peng, SONG Jianling, FANG Xiangdong. Recent Developments in Parathyroid Hormone Type 1 Receptor and Kidney Disease [J]. Chinese General Practice, 2023, 26(11): 1398-1403.
[8]	HU Shuwei, OU Wei, WANG Zhi, PENG Juan. Eye Movement Desensitization and Reprocessing versus Sertraline in the Treatment of Depressed Adolescents with Childhood Trauma [J]. Chinese General Practice, 2023, 26(06): 692-698.
[9]	DU Yeming, ZHANG Yunqiao, HAN Min, WANG Yanfang. A Comparative Study of Event-related Potential N400 between Anxious and Melancholic Depression [J]. Chinese General Practice, 2022, 25(36): 4546-4553.
[10]	ZHAO Wei, YANG Shanshan, TANG Rongjie, YANG Fang, SUN Feng, LIAN Qiufang. Correlation between Serum Thyroid Hormone and Hyperuricemia in Euthyroid Hypertensive Patients [J]. Chinese General Practice, 2022, 25(35): 4394-4398,4405.
[11]	Shaokun WANG, Shiqiang WANG, Yijie WANG, Zhihan XU. Research Progress on the Effect of Exercise and Neurobiological Mechanism on Depression [J]. Chinese General Practice, 2022, 25(27): 3443-3451.
[12]	Qian YANG, Hua LU, Qianchen LIU. Characteristics of Metabolic Calorific Values Measured by Infrared Thermal Imaging in Female Adults with Hashimoto's Thyroiditis: an Exploratory Analysis [J]. Chinese General Practice, 2022, 25(18): 2255-2261.
[13]	Anbang LIU, Cheng JIANG, Han YIN, Huan MA, Qingshan GENG. Association between Free Triiodothyronine and Depression in Patients with Coronary Heart Disease [J]. Chinese General Practice, 2022, 25(14): 1707-1712.
[14]	LU Heli, LIU Yun, HUANG Zewen, GUO Ming, HUANG Xiaoqin, XU Xi, WANG Biyi, DONG Xiangli, LI Guanhua, HU Feihu. Development and Application Effect of Knowledge-to-action Framework-based Health Management in Adolescents with Depressive Disorder in Remote Counties [J]. Chinese General Practice, 2022, 25(11): 1373-1377.
[15]	YANG Rongjun, SHI Yufang, WANG Qinghai. Advances in Mechanism of Coexistence and Pharmaceutical Treatment of Chronic Heart Failure and Depression [J]. Chinese General Practice, 2022, 25(05): 625-630.